Author

G. Mayer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:proteomics· 5 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Organism:bacteria (other)· 2 Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Friedler· 2 shared A. Weber· 2 shared T. Garfagnini· 2 shared A. Esser· 1 shared A. Moeglich· 1 shared A. Ranzani· 1 shared A. Rouvinski· 1 shared A. Schmitz· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 8 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Friedler

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Binding of SARS-CoV-2 nucleocapsid protein to uninfected epithelial cells induces antibody-mediated complement deposition

J. Fahoum, M. Billan, J. K. Varga, D. Padawer, M. Elgrably-Weiss, P. Basu, M. Stolovich-Rain, L. Baraz, S. Kumari, E. Oiknine-Dijan, M. Kumar, E. Cohen-Kfir, O. Zelig, G. Mayer, M. N. Isupov, , A. Rouvinski

This study shows that SARS-CoV-2 nucleocapsid protein binds to uninfected cells, triggering antibody-mediated complement activation in COVID-19 patients.

bioRxiv · Mar 17, 2024 · PreprintImmunology

FibrilPaint to determine the length of Tau amyloids in fluids

J. Aragones Pedrola, F. A. Dekker, T. Garfagnini, G. Mayer, M. B. Koopman, M. Bergmeijer, F. Forster, J. J. Hoozemans, H. Jensen, A. Friedler, S. G. Rudiger

FibrilPaint1 measures Tau amyloid fibril length in fluids using fluorescence and microfluidics, enabling diagnostic and research applications in neurodegenerative diseases.

bioRxiv · Oct 13, 2023 · PreprintBiochemistry

Metabolization of alpha-D-carba-glucosamine in vivo generates antimetabolites of cell wall precursors

M. Mund, S. Friz, A. Esser, D. Matzner, B. Babczyk, D. Menche, H. Broetz-Oesterhelt, C. Mayer, G. Mayer

This study shows that CGlcN is metabolized into carba-metabolites that inhibit bacterial cell wall synthesis, revealing a new antimetabolite mechanism of action.

bioRxiv · Feb 8, 2023 · PreprintMicrobiology

A peptide strategy for inhibiting different protein aggregation pathways in disease

T. Garfagnini, L. Ferrari, M. Koopman, S. Halters, E. Van Kappel, G. Mayer, M. Maurice, S. Rudiger, A. Friedler

The paper develops a peptide strategy that inhibits both amorphous and amyloid protein aggregation by targeting early aggregation stages, showing effectiveness against unrelated proteins like Axin and Tau.

bioRxiv · Oct 22, 2022 · PreprintBiochemistry

Light-dependent Control of Bacterial Expression at the mRNA Level

A. Ranzani, M. Wehrmann, J. Kaiser, M. Juraschitz, A. Weber, G. Pietruschka, G. Mayer, A. Moeglich

This paper develops optogenetic systems using the PAL photoreceptor to control bacterial gene expression at the mRNA level through light-responsive RNA aptamers.

bioRxiv · Jul 30, 2022Biochemistry

A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism

A. Schmitz, A. Weber, M. Bayin, S. Breuers, M. Famulok, G. Mayer

This study identifies an aptamer that inhibits SARS-CoV-2 pseudovirus infection without targeting the RBD or ACE2 interaction.

bioRxiv · Dec 23, 2020Biochemistry